enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,000 shares, a decrease of 60.0% from the October 15th total of 2,500 shares. Based on an average daily trading volume, of 3,300 shares, the short-interest ratio is presently 0.3 days.

enGene Price Performance

NASDAQ:ENGNW remained flat at $1.35 during trading hours on Wednesday. The business’s fifty day moving average is $1.68 and its 200 day moving average is $1.81. enGene has a 1-year low of $0.40 and a 1-year high of $6.50.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.